You are here: Industry Insights > LY-CoV555

News List

Lilly Provides Update on SARS-CoV-2 Neutralizing Antibody Programs americanpharmaceuticalreview
October 14, 2020
Eli Lilly and Company announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies ...
Eli Lilly seeks EUA for monotherapy against Covid-19 pharmaceutical-technology
October 10, 2020
Eli Lilly has submitted an application to the US Food and Drug Administration (FDA) seeking emergency use authorisation (EUA) for LY-CoV555 monotherapy for treating higher-risk patients with mild-to-moderate Covid-19.
Lilly’s COVID-19 antibody shows promise in mid-stage study pharmatimes
September 18, 2020
Eli Lilly has reported interim analysis from a Phase II study of its antibody LY-CoV555 in mild-to-moderate recently diagnosed COVID-19 patients, and the data is promising.
Two Phase III trials in US to evaluate efficacy of mAbs against COVID-19 europeanpharmaceuticalreview
August 13, 2020
Two randomised Phase III clinical trials to test mAbs against COVID-19 are now enrolling healthy adults in the US, the NIH has announced.
AbCellera provides Covid-19 programme update with start of phase 3 clinical trials pharmaceutical-business-review
August 05, 2020
AbCellera announced that LY-CoV555, a human antibody discovered by AbCellera in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC) and co-developed with Eli Lilly and Company (Lilly) as ...
Lilly begins world's first study of a potential COVID-19 antibody treatment in humans worldpharmanews
June 29, 2020
Eli Lilly and Company announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.
Second of Lilly’s COVID-19 neutralising antibodies begins Phase I trials europeanpharmaceuticalreview
June 11, 2020
The first patient has been dosed in the Chinese Phase I trial of JS016 in healthy people who do not have a COVID-19 diagnosis.
Lilly and Junshi Biosciences Initiate Phase I COVID-19 Trials contractpharma
June 10, 2020
Studies will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of JS016 in healthy participants who have not been diagnosed with COVID-19.
Lilly launches Phase I trial of investigational COVID-19 antibody treatment europeanpharmaceuticalreview
June 05, 2020
The enterprise announced the initiation of the LY-CoV555 COVID-19 antibody treatment trial at medical centres across the US.
Lilly, AbCellera Dose First Patients with COVID-19 Antibody contractpharma
June 02, 2020
Phase 1 study of LY-CoV555 is the world's first study of a potential antibody treatment designed to fight COVID-19.